Port Erin Biopharma Investments Limited
("Port Erin" or "the Company")
Net Asset Value calculation for the third trading quarter to 30th June 2012
Jim Mellon, Chairman, commented: -
"The Net Asset Value calculation for the Company as at closing on 30th June 2012 was 9.46 pence per share, including un-invested cash of £237,391. The portfolio is valued at bid price. This represents a marginal decline from last quarter's valuation, but still maintains a satisfactory 14% gain on the initial net funds raised at inception."
|
|
|
Unaudited 15 September 2011 to 30 June 2012 £ |
|
Fixed Assets |
|
|
|
|
Investments
|
2,892,182 |
|
Current Assets |
|
|
|
|
Debtors: amounts owing |
9,511 |
|
|
Uninvested cash
|
237,391 |
|
Current Liabilities |
|
|
|
|
Creditors: amounts due
|
(17,431) |
|
|
|
3,121,653 |
|
Capital and Reserves |
|
|
|
|
Share Capital |
33 |
|
|
Share Premium |
3,000,967 |
|
|
Capital reserve - realised |
0 |
|
|
Capital reserve - unrealised |
0 |
|
|
Revenue reserve
|
120,653 |
|
|
|
3,121,653 |
|
|
|
|
|
Shares in Issue
|
|
33,000,000 |
|
Net Asset Value per share
|
|
9.46 pence |
|
|
Detailed Portfolio |
|
|
Holding |
£ Value @ 30/06/12 |
Portfolio % |
|
254,109 |
8.8% |
|
|
Synergy Pharmaceuticals Inc. |
242,293 |
8.4% |
|
Plethora Solutions Holdings |
241,045 |
8.3% |
|
Pfizer Inc. |
217,778 |
7.5% |
|
Novartis AG |
160,387 |
5.5% |
|
Gilead Sciences Inc. |
141,167 |
4.9% |
|
Astellas Pharmaceuticals Inc. |
140,607 |
4.9% |
|
Summit Corporation plc |
128,055 |
4.4% |
|
119,680 |
4.1% |
|
|
101,564 |
3.5% |
|
|
86,706 |
3.0% |
|
|
Immunocellular Therapeutics Ltd. |
85,760 |
3.0% |
|
H. Lundebeck A/S |
73,848 |
2.6% |
|
72,652 |
2.5% |
|
|
68,069 |
2.4% |
|
|
64,372 |
2.2% |
|
|
Map Pharmaceuticals Inc. |
64,138 |
2.2% |
|
63,169 |
2.2% |
|
|
57,508 |
2.0% |
|
|
55,139 |
1.9% |
|
|
Siga Technologies Inc. |
42,121 |
1.5% |
|
Thershold Pharmaceuticals, Inc. |
41,406 |
1.4% |
|
Synta Pharmaceuticals Inc. |
40,556 |
1.4% |
|
37,283 |
1.3% |
|
|
Keryx Biopharmaceuticals Inc. |
34,578 |
1.2% |
|
Miraculins Inc. |
30,057 |
1.0% |
|
27,628 |
1.0% |
|
|
Orexigen Therapeutics, Inc. |
26,510 |
0.9% |
|
Methylgene Inc. |
19,648 |
0.7% |
|
Pacific Biosciences California Inc. |
17,460 |
0.6% |
|
Complete Genomics Inc. |
16,079 |
0.6% |
|
Polymedix Inc. |
14,215 |
0.5% |
|
Synergy - warrants (publicly traded) |
10,547 |
0.4% |
|
Loan: Ampliphi Biosciences Corp. |
64,033 |
2.2% |
|
Loan: Spiritus Pharmaceuticals, LLC |
32,016 |
1.1% |
|
|
|
|
|
|
2,892,182 |
100.0% |
ENDS
For further information, please contact:
|
Port Erin Biopharma Investments Ltd |
Libertas Capital Corporate Finance Limited |
Rivington Street Corporate Finance Limited |
|
The Company |
Nomad |
Broker |
|
Denham Eke +44 162 463 9396 |
Sandy Jamieson +44 207 569 9650 |
Jon Levinson +44 207 562 3350 |
